How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The firm had revenue of $32.30 million for the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period in the prior year, the firm posted ($0.44) earnings per share.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , QUALCOMM (QCOM) , Amarin (AMRN) , AbbVie (ABBV) , Gilead Sciences (gild) , OPKO Health (OPK) and Sorrento Therapeutics (SRNE) .

When did Athenex IPO?

Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

NASDAQ:ATNX

Athenex (ATNX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ATNX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.20
▼
$1.52
52-Week Range: N/A

Volume: 1.88 million shs
Average Volume: 194,316 shs
Market Capitalization: $1.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Athenex alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Athenex Stock (NASDAQ:ATNX)

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ATNX Stock News Headlines

December 26, 2023 | bizjournals.com

Biopharmaceutical company expands in time to take on Athenex business

November 22, 2023 | bizjournals.com

Only 2 local CEOs score highly with both employees and investors

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

July 31, 2023 | bizjournals.com

Athenex assets sold in bankruptcy auction; top executives dismissed

June 11, 2023 | fool.com

Athenex (NASDAQ: ATNX)

June 1, 2023 | bizjournals.com

Buffalo's drug development scene expected to continue in Athenex's wake

May 17, 2023 | bizjournals.com

Athenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-August

May 16, 2023 | uk.finance.yahoo.com

Athenex, Inc. (ATNX) stock price, news, quote & history – Yahoo Finance

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 16, 2023 | msn.com

Buffalo Billion project Athenex files for Chapter 11 bankruptcy

May 15, 2023 | msn.com

Athenex files Chapter 11

May 15, 2023 | bizjournals.com

Athenex files for bankruptcy, announces plans to sell assets

May 15, 2023 | msn.com

Why Athenex (ATNX) Stock Is Getting Obliterated Monday

May 15, 2023 | finance.yahoo.com

Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge

May 15, 2023 | marketwatch.com

Athenex Shares Tumble Premarket After Chapter 11 Filing >ATNX

May 15, 2023 | msn.com

Why Is Athenex (ATNX) Stock Down 54% Today?

May 15, 2023 | markets.businessinsider.com

Athenex Files For Chapter 11 Bankruptcy

May 14, 2023 | news.yahoo.com

Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings

May 14, 2023 | finance.yahoo.com

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

May 10, 2023 | bizjournals.com

Pine Pharmaceuticals assumes part of Athenex’s business and 50 workers

May 1, 2023 | finance.yahoo.com

Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO

April 24, 2023 | finance.yahoo.com

Athenex, Inc. (ATNX) Stock Historical Prices & Data - Yahoo Finance

April 18, 2023 | bizjournals.com

California-based Biomed Industries offers to buy Athenex

March 23, 2023 | finance.yahoo.com

Athenex (ATNX) Upgraded to Buy: Here's Why

February 14, 2023 | finance.yahoo.com

Athenex Announces a Reverse Stock Split

January 3, 2023 | finance.yahoo.com

Athenex Announces MHRA Decision on Oral Paclitaxel

December 31, 2022 | msn.com

Athenex to close Clarence plant, lay off 92 employees

See More Headlines

Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATNX
CUSIP: N/A
CIK: 1300699
Web: www.athenex.com
Phone: (716) 427-2950
Fax: N/A
Employees: 652
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($15.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-103,430,000.00
Net Margins: -86.31%
Pretax Margin: -95.92%
Return on Equity: -727.79%
Return on Assets: -44.44%

Debt

Debt-to-Equity Ratio: 3.08
Current Ratio: 1.09
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: $102.82 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.07) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 8,660,000
Free Float: 7,866,000
Market Cap: $1.76 million
Optionable: Optionable
Beta: 1.36

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Yiu Nam Lau
Chairman & Chief Executive Officer
Jeff Yordon
COO & President-Athenex Pharmaceutical Division
Joe Annoni
Chief Financial Officer
Darrel P. Cohen
Chief Medical Officer
William Zuo
President-China Operations

Key Competitors

View All Competitors

ATNX Stock Analysis - Frequently Asked Questions

How were Athenex's earnings last quarter?: Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The firm had revenue of $32.30 million for the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period in the prior year, the firm posted ($0.44) earnings per share.
What other stocks do shareholders of Athenex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).
When did Athenex IPO?: Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

This page (NASDAQ:ATNX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Athenex (ATNX) Stock Price, News & Analysis

About Athenex Stock (NASDAQ:ATNX)

ATNX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ATNX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info